vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and Purple Innovation, Inc. (PRPL). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $140.7M, roughly 2.0× Purple Innovation, Inc.). Purple Innovation, Inc. runs the higher net margin — -2.3% vs -45.7%, a 43.4% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 9.1%). Purple Innovation, Inc. produced more free cash flow last quarter ($-7.8M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 8.3%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Purple Carrot is a Needham, Massachusetts-based, and 100% plant-based meal kit company. Founded by Andy Levitt, it offers both prepared meals as well as meal kits to subscribers weekly. As stated in a 2022 article in Cosmopolitan, “each Purple Carrot meal kit results in 72% less carbon being released into the atmosphere as compared to the standard American meal.”
GH vs PRPL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $140.7M |
| Net Profit | $-128.5M | $-3.2M |
| Gross Margin | 64.6% | 41.9% |
| Operating Margin | -43.0% | -1.6% |
| Net Margin | -45.7% | -2.3% |
| Revenue YoY | 39.4% | 9.1% |
| Net Profit YoY | -15.8% | 62.1% |
| EPS (diluted) | $-1.01 | $0.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $140.7M | ||
| Q3 25 | $265.2M | $118.8M | ||
| Q2 25 | $232.1M | $105.1M | ||
| Q1 25 | $203.5M | $104.2M | ||
| Q4 24 | $201.8M | $129.0M | ||
| Q3 24 | $191.5M | $118.6M | ||
| Q2 24 | $177.2M | $120.3M | ||
| Q1 24 | $168.5M | $120.0M |
| Q4 25 | $-128.5M | $-3.2M | ||
| Q3 25 | $-92.7M | $-11.7M | ||
| Q2 25 | $-99.9M | $-17.3M | ||
| Q1 25 | $-95.2M | $-19.1M | ||
| Q4 24 | $-111.0M | $-8.5M | ||
| Q3 24 | $-107.8M | $-39.2M | ||
| Q2 24 | $-102.6M | $27.0K | ||
| Q1 24 | $-115.0M | $-50.2M |
| Q4 25 | 64.6% | 41.9% | ||
| Q3 25 | 64.7% | 42.8% | ||
| Q2 25 | 65.0% | 35.9% | ||
| Q1 25 | 63.3% | 39.4% | ||
| Q4 24 | 61.6% | 42.9% | ||
| Q3 24 | 61.1% | 29.7% | ||
| Q2 24 | 59.1% | 40.7% | ||
| Q1 24 | 61.2% | 34.8% |
| Q4 25 | -43.0% | -1.6% | ||
| Q3 25 | -37.3% | -10.2% | ||
| Q2 25 | -45.9% | -13.5% | ||
| Q1 25 | -54.6% | -13.9% | ||
| Q4 24 | -62.4% | -6.0% | ||
| Q3 24 | -61.3% | -39.5% | ||
| Q2 24 | -56.8% | -12.1% | ||
| Q1 24 | -59.2% | -19.3% |
| Q4 25 | -45.7% | -2.3% | ||
| Q3 25 | -35.0% | -9.9% | ||
| Q2 25 | -43.0% | -16.5% | ||
| Q1 25 | -46.8% | -18.4% | ||
| Q4 24 | -55.0% | -6.6% | ||
| Q3 24 | -56.3% | -33.1% | ||
| Q2 24 | -57.9% | 0.0% | ||
| Q1 24 | -68.2% | -41.8% |
| Q4 25 | $-1.01 | $0.03 | ||
| Q3 25 | $-0.74 | $0.11 | ||
| Q2 25 | $-0.80 | $0.16 | ||
| Q1 25 | $-0.77 | $0.18 | ||
| Q4 24 | $-0.90 | $0.08 | ||
| Q3 24 | $-0.88 | $0.36 | ||
| Q2 24 | $-0.84 | $0.00 | ||
| Q1 24 | $-0.94 | $0.47 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $24.3M |
| Total DebtLower is stronger | $1.5B | $126.7M |
| Stockholders' EquityBook value | $-99.3M | $-29.7M |
| Total Assets | $2.0B | $296.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $24.3M | ||
| Q3 25 | $580.0M | $32.4M | ||
| Q2 25 | $629.1M | $34.2M | ||
| Q1 25 | $698.6M | $21.6M | ||
| Q4 24 | $525.5M | $29.0M | ||
| Q3 24 | $585.0M | $23.4M | ||
| Q2 24 | $933.7M | $23.4M | ||
| Q1 24 | $1.0B | $34.5M |
| Q4 25 | $1.5B | $126.7M | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | $70.7M | ||
| Q3 24 | — | $50.8M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-99.3M | $-29.7M | ||
| Q3 25 | $-354.5M | $-26.9M | ||
| Q2 25 | $-305.5M | $-15.6M | ||
| Q1 25 | $-250.8M | $1.3M | ||
| Q4 24 | $-139.6M | $20.2M | ||
| Q3 24 | $-60.1M | $28.0M | ||
| Q2 24 | $-1.6M | $66.4M | ||
| Q1 24 | $68.3M | $65.5M |
| Q4 25 | $2.0B | $296.3M | ||
| Q3 25 | $1.3B | $302.1M | ||
| Q2 25 | $1.3B | $303.8M | ||
| Q1 25 | $1.3B | $293.8M | ||
| Q4 24 | $1.5B | $307.8M | ||
| Q3 24 | $1.5B | $309.3M | ||
| Q2 24 | $1.6B | $362.1M | ||
| Q1 24 | $1.7B | $382.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 3.50× | ||
| Q3 24 | — | 1.82× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $-5.8M |
| Free Cash FlowOCF − Capex | $-54.2M | $-7.8M |
| FCF MarginFCF / Revenue | -19.3% | -5.5% |
| Capex IntensityCapex / Revenue | 9.9% | 1.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $-41.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $-5.8M | ||
| Q3 25 | $-35.4M | $-968.0K | ||
| Q2 25 | $-60.3M | $-4.0M | ||
| Q1 25 | $-62.7M | $-23.1M | ||
| Q4 24 | $-64.5M | $6.8M | ||
| Q3 24 | $-51.1M | $1.1M | ||
| Q2 24 | $-94.0M | $-8.9M | ||
| Q1 24 | $-30.3M | $-16.8M |
| Q4 25 | $-54.2M | $-7.8M | ||
| Q3 25 | $-45.8M | $-1.8M | ||
| Q2 25 | $-65.9M | $-7.0M | ||
| Q1 25 | $-67.1M | $-25.3M | ||
| Q4 24 | $-83.4M | $5.7M | ||
| Q3 24 | $-55.3M | $101.0K | ||
| Q2 24 | $-99.1M | $-11.0M | ||
| Q1 24 | $-37.2M | $-19.9M |
| Q4 25 | -19.3% | -5.5% | ||
| Q3 25 | -17.3% | -1.5% | ||
| Q2 25 | -28.4% | -6.6% | ||
| Q1 25 | -33.0% | -24.3% | ||
| Q4 24 | -41.3% | 4.4% | ||
| Q3 24 | -28.9% | 0.1% | ||
| Q2 24 | -55.9% | -9.2% | ||
| Q1 24 | -22.1% | -16.5% |
| Q4 25 | 9.9% | 1.4% | ||
| Q3 25 | 3.9% | 0.7% | ||
| Q2 25 | 2.4% | 2.8% | ||
| Q1 25 | 2.2% | 2.2% | ||
| Q4 24 | 9.4% | 0.8% | ||
| Q3 24 | 2.2% | 0.9% | ||
| Q2 24 | 2.9% | 1.7% | ||
| Q1 24 | 4.1% | 2.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -330.22× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
PRPL
| Cost Of Revenues | $81.7M | 58% |
| Other | $59.0M | 42% |
